<DOC>
	<DOCNO>NCT00111553</DOCNO>
	<brief_summary>This study evaluate safety Leish-111f + MPL-SE vaccine adult patient cutaneous leishmaniasis .</brief_summary>
	<brief_title>Study Evaluate Leish-111F + MPL-SE Vaccine Treatment Cutaneous Leishmaniasis</brief_title>
	<detailed_description>Cutaneous leishmaniasis disfigure infection progress mucosal leishmaniasis , serious possibly fatal form leishmania infection . All available medical therapy require week treatment cause significant toxicity . In Brazil , standard therapy Glucantime treatment , administer cycle 10 consecutive , daily , intramuscular injection ( Glucantime 10 mg/kg , maximum 850 mg ) , follow 11 consecutive day without Glucantime injection ( rest day ) . At completion cycle , study physician examines patient determine cycle Glucantime treatment indicate . It appear Leishmania infection eliminate T helper 1 immune response . This finding argue vaccine augments cutaneous leishmaniasis patient ’ T helper 1 response eliminate infection disease . This study phase 1 , randomize , double-blind , placebo control , sequential dose-escalating trial evaluate safety immunogenicity three injection 5 , 10 , 20 μg Leish-111f protein + 25 μg MPL-SE adjuvant give 4 week interval adjunct standard chemotherapy Glucantime cycle , describe patient cutaneous leishmaniasis .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Confirmed diagnosis cutaneous leishmaniasis define positive identification parasite lesion biopsy Normal lab value electrocardiogram ( ECG ) Negative HIV , hepatitis B C , Chagas disease Nine active cutaneous lesion Lesion diameter &gt; 60mm Previous exposure Leishmania vaccine MPLSE Pregnant breastfeed female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Subunit vaccine</keyword>
	<keyword>Therapeutic</keyword>
	<keyword>T cell</keyword>
	<keyword>Antimony</keyword>
</DOC>